Case Number:

IPR2020-00040

Case Type:

IPR

Status:

Final Written Decision

Petitioner:

Mylan Pharmaceuticals, Inc.

Patent Owner:

Merck Sharp & Dohme Corp.

Tech Center:

1600

1. Filed: October 30, 2019 00:00

   Coverage

   1. May 13, 2020

      MDL Won't Stop PTAB From Reviewing Merck Diabetes Patent

      The Patent Trial and Appeal Board will review whether claims of a Merck patent covering the blockbuster diabetes drugs Januvia and Janumet are invalid, shooting down a variety of arguments from the drugmaker that the board should use its discretion to deny Mylan's petition.

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login